Application For Listing on Nasdaq Approved
Palatin to Trade on Nasdaq Small Cap
PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 13, 1997--Palatin Technologies Inc.
(EBB:PLTND) Monday announced that its application for listing on the Nasdaq Small Cap Market has been approved.
The company anticipates that trading of its Common Stock on the Nasdaq Small Cap Market, under the symbol PLTN, will commence on Tues., Oct. 14, 1997.
Dr. Carl Spana, executive vice president of Palatin Technologies stated, ''The move to the Small Cap Market is expected to provide Palatin with greater visibility and improved market efficiency, as
well as an ability to attract a wider investor base.''
Palatin Technologies is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical
drug development based on its proprietary monoclonal antibody, radiolabeling and enabling peptide platform technologies.
Statements about the company's future expectations, including future revenues and earnings, and all other statements in this document other than historical facts are ''forward-looking statements'' within
the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The
company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results could differ materially from expected results.
Contact:
Allen & Caron Inc
Mark Alvino (investors)
212/698-1360
Owen Daley (media)
714/252-8440
or
Palatin Technologies Inc.
Stephen T. Wills
609/520-1911 |
